Caravus, the largest locally owned employee benefits firm based in St. Louis, MO, is expanding service offerings…
Blog
Insights on Global Women’s Health App Market Size & Share to Reach USD 6611.54 Million by 2028, Exhibit a CAGR of 19.10% | Industry Trends, Value, Analysis & Forecast Report by Zion Market Research
As per Zion Market Research study, The global women’s health app marketsize was worth USD 2,316.50 million in 2021 and…
U.S. B2B Sports Nutrition Market to Reach $664.15 Million By 2027 at a CAGR of 10.27%
The “B2B Sports Nutrition Market Research Report by Application (Cognitive Repairment, Endurance, and Energy), Distribution Channel, State…
American Specialty Health Named One of Nation’s Best and Brightest in Wellness
American Specialty Health Incorporated (ASH) has been named one of the nation’s Best and Brightest Companies in…
OPEN Health to acquire leading US medical communications platform The CM Group from NaviMed Capital
OPEN Health, a global provider of scientific communications and market access services, announced that it signed…
Healthcare Equipment Leasing Market to Record a CAGR of 6.8%, Driven by Growing Demand for Equipment Leasing from Low-budget Healthcare Facilities – Technavio
The healthcare equipment leasing market is fragmented, and the vendors are deploying growth strategies such as organic and…
Localz Partners with MRI Software to Improve the Resident Experience and Drive Savings for the Social Housing Market
Localz, leading experts in last-mile location and messaging technology, have partnered with MRI Software, a global leader…
Valo Therapeutics Announces Scientific Advisory Board
Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases,…
Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Roche’s Phase III IMscin001 study evaluating a subcutaneous…
Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19
TADIOS was determined to be safe and well tolerated Serum levels of IL-1RA changed significantly, a…